Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
复制标题
DOI：
10.1002/cam4.683
复制
发表时间：
2016-06
期刊：
影响因子：
4
通讯作者：
Kikkawa F
中科院分区：
文献类型：
--
作者：
Maeda O;Miyata-Takata T;Shibata K;Kajiyama H;Mizuno M;Tamakoshi K;Shimoyama Y;Nakamura S;Kikkawa F
抗癌药物敏感性影响卵巢癌的预后。之前，我们从顺铂耐药的卵巢浆液性腺癌细胞中纯化了血影蛋白αII和βII四聚体，并证明它们有助于铂类抗癌药物耐药性。在本临床研究中，我们关注血影蛋白αII表达的作用。我们的目的是证明血影蛋白αII的表达作为一个有用的预测抗癌药物耐药和术后预后的上皮性卵巢癌的潜力。应用免疫组织化学方法检测了193例卵巢腺癌手术标本中Spectrin α Ⅱ的表达。染色强度评分为3+，视为阳性表达，2+、1+和0，视为非阳性表达。从临床记录中获得的预后进行了统计分析。在研究的193例病例中，与非阳性表达相比，血影蛋白αII阳性表达与总生存率较差相关。（对数秩检验P < 0.001），血影蛋白αII表达被确定为总生存期的独立预测因素（风险比[HR]：3.77，95%置信区间[CI]：1.77-8.00;多变量考克斯比例风险模型的P < 0.001）。在关于无进展生存期的研究中，血影蛋白αII表达与乳腺癌无关。然而，92例复发病例复发后生存期的结果与总生存期相似（对数秩检验P = 0.0051，HR：4.49，95% CI：2.06-9.79;多变量考克斯比例风险模型P < 0.001）。在66例浆液性腺癌患者和127例非浆液性腺癌患者的详细总生存率研究中，也获得了类似的结果。Spectrin αII表达可作为卵巢上皮性癌耐药及术后预后的预测指标
Anticancer drug sensitivity affects prognosis in ovarian carcinoma. Previously, we purified spectrin αII and βII tetramers from cisplatin‐resistant ovarian serous adenocarcinoma cells and demonstrated that they contribute to platinum anticancer drug resistance. In this clinical study, we focused on the role of spectrin αII expression. It is our objective to demonstrate the potential of spectrin αII expression as a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma. Spectrin αII expression in the ovarian adenocarcinoma surgical specimens of 193 patients was examined by immunohistochemical staining. Staining strength was scored 3+, regarded as positive expression, and 2+, 1+, and 0, regarded as non‐positive expression. Prognoses obtained from clinical records were evaluated by statistical analysis. In the 193 cases studied, positive spectrin αII expression was associated with worse overall survival when compared with non‐positive expression (P < 0.001 by log‐rank test), and spectrin αII expression was identified as an independent predictive factor of overall survival (hazard ratio[HR]: 3.77, 95% confidence interval[CI]: 1.77–8.00; P < 0.001 by multivariate Cox's proportional hazards model). In the study about progression‐free survival, spectrin αII expression was not associated with prognoses. However, similar results as overall survival were obtained for survival after recurrence of the 92 recurrent cases (P = 0.0051 by log‐rank test, HR: 4.49, 95% CI: 2.06–9.79; P < 0.001 by multivariate Cox's proportional hazards model). In a detailed overall survival study of 66 serous adenocarcinoma patients and 127 nonserous adenocarcinoma patients, similar results were also obtained. Spectrin αII expression is a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma..